Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...
A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors.
Reporting on ASH 2025, Dr Jamile Shammo highlights long-term follow-up data for established paroxysmal nocturnal ...
Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...
The U.S. FDA has approved Novartis AG’s Fabhalta (iptacopan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria, a rare blood disease that impairs blood cell production.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback